InnoCare Pharma Limited

HKSE 9969.HK

InnoCare Pharma Limited Shares (Diluted, Weighted) for the year ending December 31, 2023: 1,706,115,954

InnoCare Pharma Limited Shares (Diluted, Weighted) is 1,706,115,954 for the year ending December 31, 2023, a 15.31% change year over year. Shares (diluted, weighted) are the number of outstanding shares used to calculate earnings per share (EPS) assuming the conversion of all potentially dilutive securities.

InnoCare Pharma Limited Shares (Diluted, Weighted) for the year ending December 31, 2022 was 1,479,565,000, a 8.29% change year over year.
InnoCare Pharma Limited Shares (Diluted, Weighted) for the year ending December 31, 2021 was 1,366,261,000, a 41.20% change year over year.
InnoCare Pharma Limited Shares (Diluted, Weighted) for the year ending December 31, 2020 was 967,576,000, a -22.69% change year over year.
InnoCare Pharma Limited Shares (Diluted, Weighted) for the year ending December 31, 2019 was 1,251,617,235.

Key data

Date	Shares (Diluted, Weighted)	Revenue	Cost of Revenue	Gross Profit

HKSE: 9969.HK

InnoCare Pharma Limited

CEO	Dr. Jisong Cui Ph.D.
IPO Date	March 23, 2020
Location	China
Headquarters	Building 8
Employees	1,089
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

InnoCare Pharma Limited, a biopharmaceutical company, engages in discovering, developing, and commercializing drugs for the treatment of cancer and autoimmune diseases. It develops Orelabrutinib, an BTK inhibitor to treat patients with relapsed and/or refractory (r/r) chronic lymphocytic leukemia, r/r mantle cell lymphoma, r/r Waldenstrom's macroglobulinemia, r/r marginal zone lymphoma, r/r diffuse large B-cell lymphoma (DLBCL)- MCD, r/r central nervous system lymphoma, combo w/MIL-62, systemic lupus erythematosus, immune thrombocytopenia purpura, multiple sclerosis, and neuromyelitis optica spectrum disorder. The company is also developing ICP-192, a pan-FGFR inhibitor that is in a Phase I/II clinical trial for the treatment of solid tumor patients, including cholangiocarcinoma, and head and neck cancer; ICP-723, a pan-TRK inhibitor, which is in Phase I clinical trial to treat neurotrophic tyrosine receptor kinase fusion positive cancers; ICP-332, a novel tyrosine kinase 2 inhibitor that is in a Phase I clinical trial for the treatment of autoimmune diseases; and ICP-B02, a bispecific antibody for the treatment of lymphoma. In addition, it develops ICP-189, ICP-915, and ICP-B03 for the treatment of solid tumors; ICP-033 to treat liver cancer, renal cell carcinoma, colorectal cancer, and other solid tumors; ICP-488 for the treatment of autoimmune diseases; ICP-B05, an anti-CC chemokine receptor 8 monoclonal antibody for the treatment of various cancers; ICP-248 to treat hematology; and ICP-490 for the treatment of hematology and autoimmune diseases. Further, it offers ICP-B04 (Tafasitamab) to treat DLBCL/hematology. InnoCare Pharma Limited was incorporated in 2015 and is headquartered in Beijing, China.

Key trends

Past 5 years